The following training materials have been presented to examiners to ensure the robustness and reliability of patent rights. This training emanates from the U.S. Patent and Trademark Office's (USPTO) collaboration with the U.S. Food and Drug Administration (FDA) to ensure that our patent system promotes research and development and protects key innovation while not incentivizing, protecting, or permitting activity that will improperly delay competition. For more information, see USPTO's Letter to FDA, dated July 6, 2022.
- Declaration practice under 37 CFR 1.132 (Rule 132) (March 28, 2023)